Isabella Orienti

8PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersGene and molecular therapyMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 27, 2026
Cytotoxic and Cytostatic Effects of Nanoformulated Fenretinide on MG63 Osteosarcoma Cells.

Lorenzo Anconelli, Francesca Farioli, Martina Rossi

|Nov 27, 2024
Antiproliferative and Morphological Effects of Fenretinide Lipid Nanosystems in Colon Adenocarcinoma Cells.

Lorenzo Anconelli, Francesca Farioli, Pietro Lodeserto

|Mar 28, 2024
Validated LC-MS/MS Assay for the Quantitative Determination of Fenretinide in Plasma and Tumor and Its Application in a Pharmacokinetic Study in Mice of a Novel Oral Nanoformulation of Fenretinide.

Cristina Matteo, Isabella Orienti, Adriana Eramo

|Feb 25, 2023
Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine.

Lucrezia Galassi, Martina Rossi, Pietro Lodeserto

|Jul 09, 2022
Fenretinide in Cancer and Neurological Disease: A Two-Face Janus Molecule.

Rosa Luisa Potenza, Pietro Lodeserto, Isabella Orienti

|Jun 24, 2022
Nanospermidine in Combination with Nanofenretinide Induces Cell Death in Neuroblastoma Cell Lines.

Pietro Lodeserto, Martina Rossi, Paolo Blasi

Pageof 2

Frequent Collaborators

5 joint publications

Giovanna Farruggia

4 joint publications

Martina Rossi

4 joint publications

Paolo Blasi

2 joint publications

Venkatadri Kolla